

# UCLA

## UCLA Previously Published Works

### Title

Clonal hematopoiesis associated with epigenetic aging and clinical outcomes

### Permalink

<https://escholarship.org/uc/item/1m81d33g>

### Journal

Aging Cell, 20(6)

### ISSN

1474-9718

### Authors

Nachun, Daniel

Lu, Ake T

Bick, Alexander G

et al.

### Publication Date

2021-06-01

### DOI

10.1111/accel.13366

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



# Clonal hematopoiesis associated with epigenetic aging and clinical outcomes

Daniel Nachun<sup>1</sup> | Ake T. Lu<sup>2</sup> | Alexander G. Bick<sup>3</sup> | Pradeep Natarajan<sup>4,5</sup> | Joshua Weinstock<sup>6</sup> | Mindy D. Szeto<sup>7</sup> | Sekar Kathiresan<sup>4,5</sup> | Goncalo Abecasis<sup>6</sup> | Kent D. Taylor<sup>8</sup> | Xiuqing Guo<sup>8</sup> | Russ Tracy<sup>9</sup> | Peter Durda<sup>9</sup> | Yongmei Liu<sup>10</sup> | Craig Johnson<sup>11</sup> | Stephen S. Rich<sup>12</sup> | David Van Den Berg<sup>13</sup> | Cecilia Laurie<sup>11</sup> | Tom Blackwell<sup>6</sup> | George J. Papanicolaou<sup>14</sup> | Adolfo Correa<sup>15</sup> | Laura M. Raffield<sup>16</sup> | Andrew D. Johnson<sup>17</sup> | Joanne Murabito<sup>18</sup> | JoAnn E. Manson<sup>19</sup> | Pinkal Desai<sup>20</sup> | Charles Kooperberg<sup>21</sup> | Themistocles L. Assimes<sup>22</sup> | Daniel Levy<sup>17</sup> | Jerome I. Rotter<sup>8</sup> | Alex P. Reiner<sup>23</sup> | Eric A. Whitel<sup>24,25</sup> | James G. Wilson<sup>26,27</sup> | Steve Horvath<sup>2</sup> | Siddhartha Jaiswal<sup>1,28</sup> | the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium

<sup>1</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

<sup>2</sup>Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

<sup>3</sup>Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

<sup>4</sup>Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

<sup>5</sup>Broad Institute, Cambridge, MA, USA

<sup>6</sup>Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA

<sup>7</sup>Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

<sup>8</sup>Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

<sup>9</sup>Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA

<sup>10</sup>Department of Medicine, Duke University Medical Center, Durham, NC, USA

<sup>11</sup>Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA

<sup>12</sup>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

<sup>13</sup>Department of Clinical Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

<sup>14</sup>Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA

<sup>15</sup>Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

<sup>16</sup>Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC, USA

<sup>17</sup>National Heart Lung and Blood Institute, Framingham, MA, USA

<sup>18</sup>Department of Medicine, Boston University School of Medicine, Boston, MA, USA

<sup>19</sup>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>20</sup>Department of Hematology/Oncology, Joan & Sanford I. Weill Medical College of Cornell University, New York, NY, USA

<sup>21</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>22</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

**Abbreviations:** BMI, body mass index; CHD, coronary heart disease; CHIP, clonal hematopoiesis of indeterminate potential; DDR, DNA damage response; EEAA, extrinsic epigenetic age acceleration; FHS, Framingham Heart Study; HDL, high density lipoprotein; HSC, hematopoietic stem cell; hsCRP, high-sensitivity C-reactive protein; IEAA, intrinsic epigenetic age acceleration; JHS, Jackson Heart Study; LDL, low density lipoprotein; LTL, leukocyte telomere length; MESA, Multi-ethnic Study of Atherosclerosis; SNP, single nucleotide polymorphism; TOPMed, Trans-omics for Precision Medicine; VAF, variant allele fraction; WGS, whole genome sequencing; WHI, Women's Health Initiative.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Aging Cell* published by the Anatomical Society and John Wiley & Sons Ltd.



<sup>23</sup>Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA

<sup>24</sup>Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

<sup>25</sup>Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill, NC, USA

<sup>26</sup>Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA

<sup>27</sup>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

<sup>28</sup>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA

#### Correspondence

Siddhartha Jaiswal, Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.  
Email: sjaiswal@stanford.edu

#### Funding information

National Institute on Aging, Grant/Award Number: 1T32AG047126-01

#### Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is a common precursor state for blood cancers that most frequently occurs due to mutations in the DNA-methylation modifying enzymes *DNMT3A* or *TET2*. We used DNA-methylation array and whole-genome sequencing data from four cohorts together comprising 5522 persons to study the association between CHIP, epigenetic clocks, and health outcomes. CHIP was strongly associated with epigenetic age acceleration, defined as the residual after regressing epigenetic clock age on chronological age, in several clocks, ranging from 1.31 years (GrimAge,  $p < 8.6 \times 10^{-7}$ ) to 3.08 years (EEAA,  $p < 3.7 \times 10^{-18}$ ). Mutations in most CHIP genes except DNA-damage response genes were associated with increases in several measures of age acceleration. CHIP carriers with mutations in multiple genes had the largest increases in age acceleration and decrease in estimated telomere length. Finally, we found that ~40% of CHIP carriers had acceleration  $>0$  in both Hannum and GrimAge (referred to as AgeAccelHG+). This group was at high risk of all-cause mortality (hazard ratio 2.90,  $p < 4.1 \times 10^{-8}$ ) and coronary heart disease (CHD) (hazard ratio 3.24,  $p < 9.3 \times 10^{-6}$ ) compared to those who were CHIP-/AgeAccelHG-. In contrast, the other ~60% of CHIP carriers who were AgeAccelHG- were not at increased risk of these outcomes. In summary, CHIP is strongly linked to age acceleration in multiple clocks, and the combination of CHIP and epigenetic aging may be used to identify a population at high risk for adverse outcomes and who may be a target for clinical interventions.

#### KEYWORDS

clonal hematopoiesis, epigenomics, heart disease

## 1 | INTRODUCTION

Aging is inextricably associated with an increase in the number of somatic mutations, and this process is believed to be central to the development of cancer (Blokzijl et al., 2016; Hoang et al., 2016; Martincorena & Campbell, 2015; Risques & Kennedy, 2018; Welch et al., 2012). Clonal hematopoiesis of indeterminate potential (CHIP) (Jaiswal et al., 2014) is defined by the presence of a cancer-associated somatic mutation in the blood cells of people without a blood cancer or other known clonal disorder. CHIP originates when hematopoietic stem cells (HSCs) acquire a random mutation, usually in an epigenetic factor, that results in increased clone fitness (Jaiswal & Ebert, 2019). CHIP is strongly associated

with age, and carriers of these mutations have an increased risk for developing blood cancers, but also coronary heart disease (CHD) and all-cause mortality (Jaiswal et al., 2014, 2017). In addition to age, CHIP has been found to occur at a higher prevalence in males (Jaiswal et al., 2014) and a lower prevalence in people of self-reported Hispanic and East Asian ancestry compared to Europeans (Bick, Weinstock, et al., 2020; Jaiswal et al., 2014). The association of CHIP and heart disease may result from enhanced inflammatory gene expression in mutant macrophages within atherosclerotic plaques (Bick, Pirruccello, et al., 2020; Fuster et al., 2017; Jaiswal et al., 2017), demonstrating that at least some of these mutations cause dysfunction of immune cells and affect phenotypes apart from cancer.



The availability of DNA-methylation data from large epidemiological cohorts has advanced our understanding of epigenetic aging in recent years. Several “methylation clocks” have been developed (Hannum et al., 2013; Horvath, 2013; Horvath et al., 2018; Levine et al., 2018; Lu, Quach, et al., 2019) that use methylation state at a subset of CpGs to predict chronological age with high accuracy in healthy individuals. “Age acceleration” results when predicted methylation age is greater than chronological age and associates with increased risk of CHD (Levine et al., 2018; Lu, Quach, et al., 2019; Perna et al., 2016) and all-cause mortality (Chen et al., 2016; Christiansen et al., 2016; Levine et al., 2018; Lu, Quach, et al., 2019, p. 201; Marioni et al., 2015; Perna et al., 2016). Similar to prior studies (Horvath & Raj, 2018), we defined age acceleration as the residual of a linear model of a clock estimate regressed against chronological age. By definition, this measure is not correlated with chronological age and a positive (or negative) value indicates that the clock age is higher (or lower) than expected based on chronological age. The factors underlying epigenetic age acceleration are incompletely understood. Recent work has noted that two distinct categories of epigenetic clocks, intrinsic and extrinsic, which are believed to capture different aspects of aging. Intrinsic aging is independent

of cell type and may be partly driven by the number of times a cell has divided (Lu et al., 2018), while extrinsic aging, is associated with changes of cell type composition in blood (Horvath et al., 2016), and maybe influenced by environmental factors (Levine et al., 2018; Lu, Quach, et al., 2019). The Horvath and IEAA clocks reflect intrinsic aging, whereas the Hannum, EEAA, PhenoAge, and GrimAge clocks are measures of extrinsic aging (Table 1). GrimAge and PhenoAge were also trained to be predictors of mortality (Levine et al., 2018; Lu, Quach, et al., 2019). In addition, several DNA methylation-based predictors of other aging-related phenotypes have recently been developed to improve mortality prediction, such as surrogate biomarkers for plasma protein levels (adrenomedullin, beta-2-microglobulin, cystatin C, leptin, plasminogen activator inhibitor 1, tissue inhibitor matrix metalloproteinase 1) (Lu, Quach, et al., 2019), smoking pack years (Lu, Quach, et al., 2019), and telomere length (Lu, Seeboth, et al., 2019).

We hypothesized that CHIP may be an acquired genetic factor associated with epigenetic age acceleration. Here, we use whole-genome sequencing (WGS) and DNA-methylation array data from several cohorts within the Trans-omics for Precision Medicine (TOPMed) program to test the hypothesis that CHIP is linked to

**TABLE 1** Summary of epigenetic clocks used in the study

Clock	Type	Tissue	Outcome	Publication	Notes
Horvath	Intrinsic	Multiple	Chronological age	Horvath (2013)	Inaccessible tissues primarily from tissue-adjacent normal samples in The Cancer Genome Atlas (see publication)
IEAA	Intrinsic	Multiple	Chronological age	Quach et al. (2017)	Uses same CpGs as Horvath clock, but reweighted as described in Quach et al. to minimize influence of cell composition
Hannum	Extrinsic	Whole blood	Chronological age	Hannum et al. (2013)	Highly correlated with aging-related changes in blood cell composition
EEAA	Extrinsic	Whole blood	Chronological age	Quach et al. (2017)	Uses same CpGs as Hannum clock, but reweighted as described in Quach et al. to maximize influence of cell composition
SkinAndBloodClock	Intrinsic	Whole blood, fibroblasts	Chronological age	Horvath et al. (2018)	Created to address poor age prediction in Horvath clock in skin and whole blood
PhenoAge	Extrinsic	Whole blood	Time to death	Levine et al. (2018)	PhenoAge is measure of mortality risk derived from National Health and Nutrition Examination Survey using the following markers: albumin, creatinine, serum glucose, log C-reactive protein, lymphocyte percent, mean red cell volume, red cell distribution width, alkaline phosphatase, white blood cell count, and age (see publication for details)
GrimAge	Extrinsic	Whole blood	Time to death	Lu, Quach, et al. (2019)	Methylation is used to predict eight surrogate biomarkers: Adrenomedullin (ADM), Beta-2-Microglobulin (B2M), Cystatin C, Growth Differentiation Factor 15 (GDF15), Leptin, Serpin Family E Member 1 (SERPINE/PAI1), TIMP Metalloproteinase Inhibitor 1 (TIMP1), smoking pack-years (PACKYRS). The predicted values of those biomarkers are used to predict mortality (see publication for details)

Abbreviations: EEAA, extrinsic epigenetic age acceleration; IEAA, intrinsic epigenetic age acceleration.




epigenetic age acceleration. We find that CHIP is strongly associated with age acceleration in several clocks. We further assess whether there are gene-specific associations of CHIP with epigenetic age and methylation-estimated telomere length. Finally, we test whether the combination of CHIP status and epigenetic age can be used to identify the group at highest risk for adverse outcomes.

## 2 | RESULTS

### 2.1 | Association between CHIP and epigenetic age acceleration in several clocks

We used WGS data obtained from whole blood DNA for several large cohorts within TOPMed, including the Framingham Heart Study (FHS), the Jackson Heart Study (JHS), the Women's Health Initiative (WHI), and the Multi-Ethnic Study of Atherosclerosis (MESA), to identify CHIP as previously described (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020) (see Table S1 for a demographic summary of cohorts). The populations assayed for methylation were an unbiased selection from within FHS and JHS, while the WHI TOPMed samples were over-sampled for incident stroke and venous thromboembolism. The BA23 subset of WHI was a CHD case/control study. Importantly, the blood draw used for methylation array analysis was the same as that used for WGS in FHS, JHS and MESA, and in WHI, only persons for whom the blood draw for the WGS was within 3 years of the draw for methylation were included. After adjusting age acceleration residuals for sex, self-reported ancestry, and cohort, 5522 individuals, including 319 CHIP carriers, from the four cohorts were assessed for seven different aging measures: DNAmAge (Horvath) (Horvath, 2013), DNAmHannum (Hannum) (Hannum et al., 2013), DNAmPhenoAge (PhenoAge) (Levine et al., 2018), DNAmSkinClock (SkinBloodClock) (Horvath et al., 2018), DNAmGrimAge (GrimAge) (Lu, Quach, et al., 2019), intrinsic epigenetic age acceleration (IEAA) (Lu et al., 2018) and extrinsic epigenetic age acceleration (EEAA) (Lu et al., 2018), and a methylation-based estimate of telomere length (DNAmTL) (see Methods). The effects of CHIP were assessed overall (any CHIP mutation), as well as at the level of specific classes of CHIP mutations (see Methods).

Consistent with previous results, carriers of CHIP were significantly older than non-carriers ( $+7.23 \pm 0.61$  years,  $p < 1.13 \times 10^{-31}$ , Figures S1 and S2), and the prevalence of CHIP reached >20% in those over 80 years (Figure S1). We then tested whether age acceleration residuals from several clocks bore any association to CHIP (Figure 1). Similar to the results of Robertson et al. (2019), CHIP was most strongly associated with intrinsic age acceleration (Horvath: 3.01 years,  $p < 3.0 \times 10^{-25}$ ; IEAA: 2.92 years,  $p < 9.3 \times 10^{-26}$ ). Due to our larger sample size, we also observed strong associations between CHIP and extrinsic age acceleration (Hannum clock: 2.71 years,  $p < 1.8 \times 10^{-23}$ ; EEAA: 3.08 years,  $p < 3.7 \times 10^{-18}$ ), as well as PhenoAge (2.21 years,  $p < 1.0 \times 10^{-8}$ ), SkinBloodClock (1.58 years,  $p < 2.5 \times 10^{-13}$ ), and GrimAge (1.31 years,  $p < 8.6 \times 10^{-7}$ ). We also found that the number of driver mutations was associated with a



**FIGURE 1** CHIP is associated with increased age acceleration. Forest plot of the effect sizes and confidence intervals for the effect of CHIP on age acceleration estimate from seven methylation clocks

stepwise increase in age acceleration for several clocks, and this relationship was strongest for Hannum and EEAA (Table S2).

We also found modest associations between CHIP and several epigenetic surrogate markers of plasma proteins as well as blood counts (Table S3A,B), and between clock estimates and variant allele fraction (VAF), which is an approximation of clone size (Table S4). Methylation data can also be used to estimate a surrogate marker of leukocyte telomere length (LTL), DNAmTL (Lu, Seeboth, et al., 2019). CHIP was associated with reduced predicted age-adjusted DNAmTL in CHIP overall ( $-0.06$ ,  $p < 1.2 \times 10^{-8}$ ), as well as several mutation classes (Figure S3A). An increasing number of mutations was associated with a decrease in predicted DNAmTL (2 mut. vs. 1:  $-0.174$ ,  $p < 8.0 \times 10^{-7}$ ; >2 mut. vs. 2:  $-0.404$ ,  $p < 1.1 \times 10^{-5}$ , Figure S3B,C).

### 2.2 | Gene-specific associations of CHIP with epigenetic age acceleration

Clonal hematopoiesis of indeterminate potential most commonly occurs due to mutations in genes coding for the DNA methylation-altering enzymes *DNMT3A* and *TET2*, but can also arise due to mutations in *ASXL1*, *JAK2*, splicing factors, and DNA-damage response (DDR) genes. Accordingly, we examined the associations of mutations in specific CHIP genes with age acceleration (Table 2). In all clocks, the direction of association for *DNMT3A* and *TET2* mutations was the same, although those with *TET2* mutations had significantly greater age acceleration than those with *DNMT3A* mutations for Hannum (2.10 years,  $p < 0.0012$ ) and EEAA (2.32 years,  $p < 0.0063$ ), but not other clocks. We also performed differential methylation analysis to assess whether mutations in the DNA-methylation modifying enzymes *DNMT3A* and *TET2* had divergent effects at the clock CpGs. Mutations in both genes primarily resulted in hypomethylation although a small number of CpGs showed hypermethylation in *TET2* (Figure S4A,B). We also observed at the clock CpGs that the



M-values (a log-transformed measure of the percent methylation at each site) in persons with *DNMT3A* and *TET2* mutations were highly correlated (Figure S4C), indicating that the methylation state of persons with the two mutations is largely similar, despite their opposing enzymatic effects.

Persons with mutations in multiple genes had the largest increases in age acceleration across all clocks except PhenoAge, consistent with our observation that age acceleration increases with the number of mutations. Conversely, no increase in age acceleration was observed in persons with mutations in DDR genes (*TP53*, *PPM1D*, *BRCC3*), which is consistent with the lack of association with age acceleration observed for the same mutations in cancer tissue samples (Horvath, 2013). Although we had only eight individuals with *JAK2* mutations in our cohort, these mutations showed an exceptionally strong association for a single mutation in several clocks, the most extreme example being PhenoAge (10.01 years,  $p < 9.7 \times 10^{-6}$ ). The PhenoAge clock was trained to predict a composite measure of mortality risk which includes several hematological variables such as white blood cell count, white blood cell differential, and several red blood cell parameters which may be abnormal in myeloproliferative neoplasm, a hematological malignancy which is strongly associated with *JAK2* mutations. CHIP overall was nominally associated with estimated pack years of smoking (DNAmPACKYRS), but only mutations in *ASXL1* were significantly associated with this measure in a gene-specific analysis (7.54 pack years,  $p < 0.002$ ), a finding that is in accordance with a recent report (Bolton et al., 2020) (Table S3).

### 2.3 | Association of CHIP and epigenetic age acceleration with clinical outcomes

Several previous studies have linked both CHIP (Jaiswal et al., 2014, 2017) and age acceleration in some clocks (Levine et al., 2018; Lu, Quach, et al., 2019) to increased risk of adverse clinical outcomes, in particular all-cause mortality and CHD. We asked whether the combination of CHIP and age acceleration could further stratify carriers of CHIP into high-risk and low-risk groups for these outcomes using Cox proportional hazards models adjusted for chronological age at blood draw, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, systolic blood pressure, type 2 diabetes status, smoking status, and self-reported ancestry in 4088 persons from JHS, FHS, and WHI (Figure 2B,C). In FHS, JHS, and WHI EMPC, which are unselected for CHD, there were 720 deaths (74 in CHIP carriers) out of 3624 participants (213 CHIP carriers) and 212 cases of incident CHD (22 in CHIP carriers) out of 3331 participants (192 CHIP carriers) after excluding those with CHD prevalent to time of blood draw. In WHI BA23, which was a case-control study for CHD, there were 168 cases of incident CHD (18 in CHIP carriers) in 458 total participants (42 CHIP carriers).

We defined a person to have “age acceleration” (AgeAccel) for a clock if their values for an age acceleration residual exceeded zero after adjustment for age at blood draw, sex, self-reported ancestry, and study cohort. We then tested the interaction between

this dichotomous variable and CHIP status in predicting mortality in each of the seven clocks using Cox models. As shown in Table S5, we found that the most significant interactions were for the Hannum and GrimAge clocks, although neither reached Bonferroni-corrected statistical significance. Though both the Hannum and GrimAge clocks were predictive of time to death or CHD in previous studies (Lu, Quach, et al., 2019; Marioni et al., 2015; Perna et al., 2016), they were trained on different outcomes (age for Hannum versus time to death for GrimAge), and are not strongly correlated in our dataset (bicor = 0.242,  $R^2 = 0.058$ , Figure 2A). Therefore, we reasoned that a combined measure incorporating age acceleration in both Hannum and GrimAge would better stratify high- and low-risk groups because each clock provides orthogonal information. By this combined measure (henceforth referred to as AgeAccelHG), 102/255 (40%) of CHIP carriers were AgeAccelHG+ (age acceleration residual >0 for both Hannum and GrimAge), compared to 922/3833 (24%) persons without CHIP. Considered individually in separate models, CHIP and AgeAccelHG were each associated with a modest increase in risk of all-cause mortality (CHIP: HR 1.27,  $p < 0.077$ ; AgeAccelHG: HR 1.84,  $p < 4.0 \times 10^{-14}$ ), consistent with previous findings. When we modeled the interaction of CHIP with AgeAccelHG for all-cause mortality, we found a significant interaction effect (CHIP main effect: coefficient = -0.25,  $p < 0.20$ ; AgeAccelHG main effect: coefficient = 0.51,  $p < 3.08 \times 10^{-9}$ ; interaction: coefficient = 0.80,  $p < 3.74 \times 10^{-3}$ ), which remained significant after Bonferroni correction for eight tests.

To validate this finding, we sought replication in an independent cohort, the BA23 subset of WHI, which was not used in the above mortality analysis (Horvath et al., 2016). When we modeled the interaction of CHIP with AgeAccelHG for CHD in BA23, the interaction term was again significant (CHIP main effect: coefficient = -0.24,  $p < 0.60$ ; AgeAccelHG main effect: coefficient = 0.24,  $p < 0.35$ ; interaction: coefficient = 1.72,  $p < 0.01$ ).

Having demonstrated a significant statistical interaction between CHIP and AgeAccelHG for clinical outcomes, we combined these two variables into a single, 4-factor variable for further modeling. For CHD, we included incident events in FHS, JHS, and WHI EMPC together with WHI BA23 as a meta-analysis. Persons who were CHIP+/AgeAccelHG+ had much greater risk of all-cause mortality (HR 2.90,  $p < 4.1 \times 10^{-8}$ ) and CHD (HR 3.24,  $p < 9.3 \times 10^{-6}$ ) compared to those who were CHIP-/AgeAccelHG-. Those who were CHIP-/AgeAccelHG+ had a more modest increase in risk of all-cause mortality (HR 1.66,  $p < 3.1 \times 10^{-9}$ ), and CHD (HR 1.39,  $p < 0.012$ ) compared to those who were CHIP-/AgeAccelHG-. In contrast, those who were CHIP+/AgeAccelHG- did not have elevated risk of either all-cause mortality (HR 0.78,  $p < 0.20$ ) or CHD (HR 1.03,  $p < 0.93$ ) compared to those who were CHIP-/AgeAccelHG- (Figure 2B,C). We also fitted contrasts to estimate the hazard ratios for all-cause mortality and CHD for CHIP only in persons with AgeAccelHG+ and AgeAccelHG+ only in persons with CHIP, in both cases finding the associations to be significant (Figure S5).

We also asked if there were gene-level differences in risk of these outcomes. We had insufficient sample size to assess





TABLE 2 CHIP mutations in specific classes of genes have largely consistent effects on age acceleration

Class	Horvath		IEAA		Hamnum		EEAA		SkinBloodClock		PhenoAge		GrimAge	
	Est. (SE)	p-value	Est. (SE)	p-value	Est. (SE)	p-value	Est. (SE)	p-value	Est. (SE)	p-value	Est. (SE)	p-value	Est. (SE)	p-value
All	3.01 (0.27)	$3.0 \times 10^{-25}$	2.92 (0.26)	$9.30 \times 10^{-26}$	2.71 (0.26)	$1.80 \times 10^{-23}$	3.08 (0.33)	$3.70 \times 10^{-18}$	1.58 (0.20)	$2.50 \times 10^{-13}$	2.21 (0.36)	$1.00 \times 10^{-08}$	1.31 (0.25)	$8.60 \times 10^{-07}$
DNMT3A	2.58 (0.38)	$2.20 \times 10^{-10}$	2.72 (0.36)	$2.10 \times 10^{-12}$	1.76 (0.35)	$5.70 \times 10^{-06}$	1.75 (0.46)	$6.80 \times 10^{-04}$	1.44 (0.28)	$1.80 \times 10^{-06}$	2.16 (0.51)	$5.80 \times 10^{-05}$	0.61 (0.35)	0.123
TET2	2.58 (0.59)	$4.80 \times 10^{-05}$	2.47 (0.57)	$4.90 \times 10^{-05}$	3.86 (0.55)	$2.10 \times 10^{-11}$	4.07 (0.72)	$7.20 \times 10^{-08}$	0.91 (0.44)	0.06	1.31 (0.79)	0.135	0.99 (0.55)	0.093
Multiple	7.43 (0.93)	$5.60 \times 10^{-15}$	6.77 (0.89)	$1.10 \times 10^{-13}$	8.36 (0.86)	$3.0 \times 10^{-21}$	10.97 (1.13)	$2.50 \times 10^{-21}$	5.01 (0.69)	$1.00 \times 10^{-12}$	6.35 (1.24)	$5.30 \times 10^{-07}$	4.85 (0.85)	$2.40 \times 10^{-08}$
DDR	0.21 (1.06)	0.962	-0.21 (1.01)	0.717	0.31 (0.98)	0.871	1.43 (1.29)	0.327	-0.26 (0.79)	0.66	0.63 (1.41)	0.718	-0.27 (0.97)	0.723
JAK2	3.80 (1.67)	0.029	1.37 (1.60)	0.448	5.88 (1.56)	$2.30 \times 10^{-04}$	6.21 (2.04)	0.003	4.31 (1.24)	$6.70 \times 10^{-04}$	10.01 (2.23)	$9.70 \times 10^{-06}$	3.46 (1.54)	0.028
ASXL1/2	2.86 (1.06)	0.011	2.75 (1.01)	0.011	1.46 (0.98)	0.183	1.87 (1.29)	0.188	0.44 (0.79)	0.652	-0.55 (1.41)	0.634	3.11 (0.97)	0.002
Splicing factor	5.02 (1.57)	0.002	4.88 (1.51)	0.002	2.70 (1.47)	0.082	2.41 (1.92)	0.242	2.36 (1.17)	0.052	2.46 (2.11)	0.267	2.37 (1.45)	0.112
Other	4.20 (1.31)	0.002	4.40 (1.26)	$7.30 \times 10^{-04}$	0.98 (1.22)	0.497	1.68 (1.60)	0.345	1.99 (0.97)	0.05	0.73 (1.75)	0.726	1.95 (1.21)	0.12


Note: Table with effect sizes, standard errors, and p-values for eight different classes of CHIP mutations. "Multiple" means mutations in multiple genes. "DDR" refers to mutations in the DNA damage response genes TP53, PPM1D, and BRCC3. "Splicing factor" are mutations in SF3B1, SRSF2, U2AF1, ZRSR2, and PRPF8. "Other" refers to mutations in all other genes not listed.

either mortality or CHD individually, so we combined the two into a composite outcome. Being AgeAccelHG+ increased the risk of the composite outcome for those with TET2 mutations relative to those who were CHIP-/AgeAccelHG- (TET2 mutated+/AgeAccelHG+: HR = 3.88,  $p < 1.6 \times 10^{-6}$ ; TET2 mutated+/AgeAccelHG-: HR = 1.14,  $p < 0.66$ ;  $p$  for interaction  $< 0.065$ ) to a greater degree than those with DNMT3A mutations (DNMT3A mutated+/AgeAccelHG+: HR = 1.99,  $p < 0.028$ ; DNMT3A mutated+/AgeAccelHG-: HR = 0.68,  $p < 0.079$ ;  $p$  for interaction  $< 0.11$ ) or other non-DDR mutations (other mutation+/AgeAccelHG+: HR = 2.88,  $p < 1.1 \times 10^{-5}$ ; other mutation+/AgeAccelHG-: HR = 1.00,  $p < 1$ ;  $p$  for interaction  $< 0.19$ ).

To illustrate absolute risks among those with both CHIP and AgeAccelHG, we determined the cumulative incidence of all-cause mortality and CHD in persons from FHS, JHS, and WHI EMPC aged 65 or older at blood draw who did not have prevalent CHD (Figure 2D,E). Those who were CHIP+/AgeAccelHG+ had a cumulative incidence of all-cause mortality of 46.6% by 10 years and a cumulative incidence of CHD of 22.2% by 10 years. In contrast, the other three groups had substantially lower 10-year cumulative incidence of all-cause mortality (CHIP+/AgeAccelHG- 17.7%, CHIP-/AgeAccelHG+ 25.8%, CHIP-/AgeAccelHG- 19.2%) and CHD (CHIP+/AgeAccelHG- 7.98%, CHIP-/AgeAccelHG+ 13.0%, CHIP-/AgeAccelHG- 8.66%).

Our data permitted us to also ask whether there was an association of CHIP and AgeAccelHG to time to death in those who had a first CHD event, a subgroup that is often the target of clinical interventions. We restricted our analysis to individuals who had a first CHD event after age 70 and, if they died, did so more than 30 days after the CHD event. We found a significant interaction between CHIP and AgeAccelHG for all-cause mortality after CHD ( $p < 0.036$ ). Persons who were CHIP+/AgeAccelHG+ showed significant increase in risk of all-cause mortality (HR = 3.16,  $p < 1.16 \times 10^{-5}$ ), while those who were CHIP+/AgeAccelHG- (HR = 0.462,  $p < 0.27$ ) or CHIP-/AgeAccelHG+ (HR = 1.40,  $p < 0.13$ ) showed no significant increase. The 5-year cumulative incidence of death after CHD for those who were CHIP+/AgeAccelHG+ was 58.5%, while for all other groups it was substantially lower (CHIP+/AgeAccelHG- 18.8%, CHIP-/AgeAccelHG+ 20.0%, CHIP-/AgeAccelHG- 19.8%, Figure 2F).

Given the previous findings linking both CHIP (Jaiswal et al., 2017) and extrinsic epigenetic aging (Horvath et al., 2016; Levine et al., 2018; Lu, Quach, et al., 2019) to inflammation, we asked whether plasma levels of the inflammation marker high-sensitivity C-reactive protein (hs-CRP) showed any evidence of interaction with CHIP for all-cause mortality or CHD. We found evidence for a main effect of hs-CRP on risk for all-cause mortality, but not for an interaction with CHIP (CHIP main effect: coefficient = 0.22,  $p < 0.22$ ; log (hs-CRP) main effect: coefficient = 0.09,  $p < 1.01 \times 10^{-3}$ ; interaction: coefficient = 0.076,  $p < 0.29$ ). For CHD, no effect of hs-CRP was observed (CHIP main effect: coefficient = 0.23  $p < 0.49$ ; log (hs-CRP) main effect: coefficient = 0.01,  $p < 0.90$ ; interaction: coefficient = -0.3,  $p < 0.82$ ). We also stratified our cohort into eight groups based upon CHIP status, AgeAccelHG status, and whether hs-CRP



**FIGURE 2** CHIP and epigenetic age acceleration identify persons at high risk of all-cause mortality and development of coronary heart disease (CHD). (a) Scatterplot of correlation between AgeAccelGrim and AgeAccelHannum in all cohorts. (b, c) Forest plots showing hazard ratios, confidence intervals, and  $p$ -values for Cox proportional hazard models of all-cause mortality (b) and development of CHD (c) in persons from FHS, JHS, and WHI. All models included chronological age, race, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, systolic blood pressure, type 2 diabetes status and smoking status as covariates. Top two sections show the overall effect size of CHIP and age acceleration and bottom section shows effect sizes based on dividing persons into four groups based upon presence of CHIP and age acceleration. The results in c are a meta-analysis of events in FHS, JHS, WHI EMPC (unselected for CHD), and WHI BA23 (case-control study for CHD). (d, e) Cumulative incidence plots of death (d) and CHD (e) in persons divided into groups by the presence of CHIP (CHIP+/CHIP-) and age acceleration (AgeAccelHG+/AgeAccelHG-). The numbers in parentheses indicate the number of persons in each group for these analyses. Only persons over 65 and free of CHD at baseline were used in d and e, while all persons were used for b and c. (f) Cumulative incidence plot of death in persons with incident CHD after age 70. Individuals who died less than 30 days after CHD were excluded

levels were above 2 mg/L, an established clinical cutoff. Individuals with CHIP and AgeAccelHG showed a similar risk of all-cause mortality and CHD regardless of whether they had high or low hs-CRP levels (Figure S5E,F). These results indicate that hs-CRP is a poor discriminator of risk in CHIP carriers, unlike AgeAccelHG.

A coding SNP in *IL6R* (rs2228145), which results in Asp358Ala, was previously found to attenuate the increased risk for mortality and CHD associated with CHIP (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020). Here, the interaction between CHIP status and alternate allele count at rs2228145 was not significant for either all-cause mortality (CHIP main effect: coefficient = 0.27,  $p < 0.158$ ; rs2228145 main effect: coefficient =  $-0.082$  per alternate allele,  $p < 0.21$ ; interaction: coefficient =  $-0.044$  per alternate allele,  $p < 0.82$ ) or CHD (CHIP main effect: coefficient = 0.23,  $p < 0.36$ ; rs2228145 main effect: coefficient =  $-0.16$  per alternate allele,  $p < 0.08$ ; interaction: coefficient = 0.25 per alternate allele,  $p < 0.36$ ). There were also no significant interactions between rs2228145 genotype and the combined CHIP/AgeAccelHG variable (Figure S5C,D). These results indicate that *IL6R* genotype is a poor discriminator of risk in CHIP carriers in this dataset, unlike AgeAccelHG. However, we did find differences based on which gene was mutated. Those who were *TET2*-CHIP+/AgeAccelHG+

and with no alternate alleles of rs2228145 (*IL6R*WT) had the highest risk for the composite mortality/CHD outcome relative to the referent group of CHIP-/AgeAccelHG-/*IL6R*WT (HR = 11.3,  $p < 2.4 \times 10^{-21}$ , Figure S6). Those who were *TET2*-CHIP+/AgeAccelHG+ but carried 1 or 2 alternate alleles of rs2228145 (*IL6R*Mut) had substantially lower risk (HR = 1.91 compared to the same referent group,  $p < 0.066$ ; coefficient for interaction =  $-1.12$  per alternate allele,  $p$  for interaction  $< 9.6 \times 10^{-7}$ , Figure S6). There was no significant difference in risk based on rs2228145 genotype in those who were *TET2*-CHIP+/AgeAccelHG-. We also did not find significant differences in risk of death/CHD by rs2228145 genotype in *DNMT3A*-CHIP or CHIP with other non-DDR mutations regardless of AgeAccelHG status.

### 3 | DISCUSSION

The results presented here permit us to draw several conclusions. First, it is clear that CHIP is strongly associated with epigenetic aging in several clocks. Consistent with the results from Robertson et al. (2019), we find the strongest associations to be with the intrinsic clocks, Horvath and IEAA. This could reflect





a shared genetic architecture, as evidenced by the overlapping GWAS hits between polymorphisms near *TERT* and *TRIM59* that associate with both CHIP and IEAA (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020; Zink et al., 2017). However, the heritability of CHIP appears to be low (3.6% Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020), which limits our ability to test for genetic correlation between CHIP and age acceleration. Previous studies have shown that IEAA of cultured fibroblasts strongly correlates with the number of population doublings (Lu et al., 2018). Therefore, an alternative hypothesis is that the increase in intrinsic age acceleration seen in CHIP carriers may be due to either (1) increased proliferation or self-renewal of HSC clones that harbor these mutations or (2) stem cell exhaustion of wild-type HSCs from over-proliferation, leading to a selective advantage for mutant clones. Studies in model systems such as genetically modified mice may help delineate the cause-effect relationship between mutations in various CHIP-associated genes and intrinsic age acceleration.

Most importantly, our results show that it is possible to stratify CHIP carriers into those at high versus low risk of adverse clinical outcomes using a composite measure of Hannum and GrimAge (AgeAccelHG). CHIP or AgeAccelHG status alone is associated with a modestly increased risk of death or CHD, but the combination of CHIP+ and AgeAccelHG+ is synergistic for these outcomes. Furthermore, CHIP in the absence of epigenetic aging in these clocks is not associated with adverse outcomes. These results suggest that the effects of CHIP on health are context-dependent, as Hannum and GrimAge are not uniformly increased in all CHIP carriers, and may be influenced by environmental factors such as CRP, smoking, diet, BMI, insulin resistance, education level, exercise, socioeconomic status (Quach et al., 2017), traumatic stress (Wolf et al., 2018), insomnia (Carroll et al., 2017), and hunter-gatherer lifestyle (Horvath et al., 2016). Our results may also explain why the strength of the associations between CHIP and mortality or CHD are somewhat inconsistent across studies—while the prevalence of CHIP is fairly uniform across populations, epigenetic aging may not be. In populations with a high prevalence of risk factors for epigenetic aging, the consequences of CHIP may be direr than in populations without such risk factors.

Our risk stratification schema may also be used to select patients for clinical trials of pharmaceutical or behavioral interventions, as the benefit-to-risk ratio may be particularly favorable in the high-risk CHIP group. We note that the 5-year mortality after CHD in those who are CHIP+ and AgeAccelHG+ approaches 60%, similar to the mortality seen in patients with intermediate-risk MDS (Greenberg et al., 2012). Furthermore, the high event rate in this group would enable smaller trials with sufficient power for detecting favorable outcomes such as reduced all-cause mortality or time to CHD. One such intervention may be blockade of IL-6 receptor (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020); our results show that those who are *TET2*-CHIP+ and AgeAccelHG+ have lower risk of death or CHD with increasing copies of rs2228145, which has

previously been linked to reduced IL-6R expression levels in myeloid cells (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020). Alternatively, this group may benefit from IL-1B inflammatory blockade (Ridker et al., 2017), which has also been shown to be relevant to atherosclerosis in model systems of CHIP (Fuster et al., 2017; Jaiswal et al., 2017). Of note, AgeAccelHG appears to be superior to hs-CRP and genotype at *IL6R* for risk discrimination of CHIP carriers, implying that it is capturing additional information beyond baseline inflammation.

In sum, our results show that there is an important relationship between CHIP and epigenetic aging. CHIP and epigenetic age acceleration can also be used to identify persons at high risk of all-cause mortality and CHD, further reinforcing the importance of both phenotypes as valuable tools in precision medicine for aging.

## 4 | METHODS

### 4.1 | Epidemiological cohorts

All participant data were obtained from four independent patient cohorts: the FHS (Feinleib et al., 1975), the JHS (Sempos et al., 1999), the WHI (phs000200.v11.p3), and the MESA (Bild, 2002, p. 200). These cohorts were included in the TOPMed consortium which is run by the National Heart Lung and Blood Institute of the National Institutes of Health. Access to all data was approved by TOPMed as well as the individual cohorts. We included only those persons from these cohorts in which the age at draw for both whole blood methylation and WGS were available. In the FHS and JHS cohorts, the samples for methylation and WGS were taken from the same blood draw in all persons. In MESA, methylation data were only used from the first exam as this was the time at which DNA for WGS was also collected. In the WHI cohort, the two samples were often taken from different times. We only considered persons for whom the methylation and WGS samples were taken within 3 years of each other.

### 4.2 | Methylation array data

Whole blood methylation was quantified using the Illumina MethylationEPIC or HumanMethylation450k array. Normalized methylation data were submitted to the online methylation clock tool (<https://dnamage.genetics.ucla.edu/new>) which generates methylation age estimates for seven different clocks: DNAmAge (Horvath, 2013), DNAmHannum (Hannum et al., 2013), DNAmPhenoAge (Levine et al., 2018), DNAmSkinClock (Horvath et al., 2018), DNAmGrimAge (Lu, Quach, et al., 2019), intrinsic epigenetic age acceleration (IEAA) (Lu et al., 2018), and extrinsic epigenetic age acceleration (EEAA) (Lu et al., 2018). Age acceleration was computed for each measure as the residual of model predicting each persons' methylation age from their chronological age at the time of blood draw. Additionally, the DNAmGrimAge clock



generates seven surrogate biomarkers based upon blood protein expression (MADM/NRBP1, B2 M, CST3 (Cystatin C), GDF15, LEP (Leptin), SERPINE1/PAI1, and TIMP1) as well smoking pack years. Age-adjusted LTL and unadjusted LTL are also estimated by the clock software (Lu, Seeboth, et al., 2019). Cell composition was also estimated by the clock software using a published model (Houseman et al., 2012).

### 4.3 | Identification of somatic variants

Approximately 100,000 whole genomes were sequenced from whole blood DNA to  $\sim 30\times$  depth as part of the TOPMed study (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020). Somatic mutations associated with CHIP were called from WGS data using the Mutect2 module in GATK from BAM files previously aligned with BWA. Candidate CHIP variants were selected based upon a curated list of known variants recurrently mutated in hematological malignancies as previously described (Jaiswal et al., 2017) (see Table S6). A full list of variants identified in this study are included in Table S7.

### 4.4 | Association between CHIP and methylation age acceleration

Clonal hematopoiesis of indeterminate potential status was associated with age acceleration and the other measures using linear modeling, with a separate model being fitted for each aging measure. Because of the relatively small number of comparisons,  $p$ -values for these analyses were reported unadjusted. We combined the data from all three studies and used residualization to remove the effects of age, race/ethnicity, sex, and study. This approach was chosen to eliminate any possibility of spurious associations between CHIP and the methylation measures that were driven by collinearity between CHIP and covariates. The residualized methylation measure was the outcome in each model, and a likelihood ratio test was performed to test the significance of CHIP as predictor against a null model containing only the intercept. When testing the association of CHIP mutations with specific genes, CHIP status was replaced with a categorical variable indicating whether the individual had a mutation in that gene, and persons with CHIP mutations in other genes were excluded. The following specific categories for single mutations were used: *DNMT3A*, *TET2*, DNA-damage response (DDR, which includes *TP53*, *PPM1D*, and *BRCC3*), *JAK2*, *ASXL1/2* (includes *ASXL1* and *ASXL2*), splicing factor (includes *SF3B1*, *SRSF2*, *U2AF1*, *ZRSR2*, and *PRPF8*), and other for any single gene which did not fit in the previous categories. Persons with mutations in more than one gene were classified as multiple regardless of the number of mutations or which genes were mutated, while persons with multiple mutations in the same gene were classified as singletons. The analysis of mutation number versus methylation measures grouped all persons with single mutation into one group, and split the group with mutations in

multiple genes into two mutations and greater than two mutations, regardless of which genes were mutated. Correlation between VAF and the residualized methylation measures was computed using bi-weight midcorrelation, an outlier resistant alternative to Pearson's correlation (Horvath, 2011).

### 4.5 | Differential methylation of clock CpGs

Illumina HumanMethylation450K and MethylationEPIC CpG probe IDs for the clocks and DNAmLTL were obtained from the supplemental data of the relevant publications. Methylation beta values for each cohort were subsetted for CpGs used in all clocks except GrimAge (for which the CpG locations have not been published) and were converted to  $M$ -values. The  $M$ -values were adjusted for the same covariates that were considered for the methylation clock measures. The adjusted residuals were tested for differential methylation and  $p$ -values were corrected for the number of CpGs tested using limma (Ritchie et al., 2015).

### 4.6 | Association of CHIP and epigenetic age acceleration with clinical outcomes

We tested the associations of CHIP and epigenetic age acceleration with all-cause mortality and incident CHD with Cox proportional hazards models using the *survival* package in R. Models included age, sex, race/ethnicity, systolic blood pressure, type 2 diabetes status, plasma LDL-cholesterol concentration, plasma HDL-cholesterol concentration, plasma triglyceride concentration, and smoking status as covariates. Some persons in WHI had DNA for the methylation and/or WGS sample obtained several years after the baseline visit, which potentially could introduce survivorship bias into the analysis. For this reason, we also excluded anyone in WHI for whom either the methylation or WGS blood draw occurred more than 5 years after the baseline visit.

For analysis of all-cause mortality, pooled data from FHS, JHS, and WHI EMPC were used. The selection of samples used in TOPMed in these cohorts were taken essentially at random from the larger parent cohorts. WHI BA23 was excluded from this analysis because persons in this cohort were over-sampled for CHD. MESA was excluded from this analysis because persons in this cohort were selected for surviving at least 10 years from baseline. We chose to present the results from models in which all three cohorts were pooled, rather than analyzed separately and then meta-analyzed. The results for the meta-analysis were similar, however (CHIP/AgeAccelHG interaction pooled: coefficient = 0.80,  $p < 3.7 \times 10^{-3}$ ; CHIP/AgeAccelHG interaction in fixed-effects meta-analysis: coefficient = 0.85,  $p < 2.4 \times 10^{-3}$ ).

For the analysis of CHD, the WHI BA23 cohort was analyzed separately, and a meta-analysis was used to combine the results of the BA23 analysis with the other pooled cohorts (JHS, FHS, and WHI EMPC) to get the final effect size estimates. 45 persons in WHI



BA23 were also included in the mortality analysis of WHI EMPC but were not included in the CHD analysis of WHI EMPC (i.e., were not double-counted). Because BA23 was over-sampled for CHD, we adjusted the sample weights in BA23 using race and incident CHD numbers in the entire dbGaP-eligible set of WHI to allow for Cox proportional hazards modeling. Robust standard errors were used to calculate *p*-values in all models.

Similar to the associations between CHIP and age acceleration, *p*-values for these analyses were reported unadjusted due to the small number of comparisons. We used the age acceleration residuals from the analysis associating CHIP with epigenetic age acceleration to determine if persons had high age acceleration (AgeAccelHG, defined as being greater than 0 for both AgeAccelHannum and AgeAccelGrim) and intersected this with CHIP status, resulting in four groups: no CHIP with low age acceleration, no CHIP with high age acceleration, CHIP with low age acceleration, and CHIP with high age acceleration. When we analyzed the interaction of individual clocks with CHIP status, we used the same definition for age acceleration but restricted it to only one clock.

For the gene-level analyses, persons with any singleton *DNMT3A*, *TET2*, or *DDR* gene (*TP53*, *PPM1D*, *BRCC3*) mutation were considered to be in those classes. All other non-*DNMT3A*, *TET2*, and *DDR* mutations were considered “other.” In those with multiple mutations, the mutated gene with the highest VAF was used to assign the class.

For the analysis of cumulative incidence of death and CHD, the *cmprsk* package in R was used.

## ACKNOWLEDGMENTS

Whole-genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung, and Blood Institute (NHLBI). WGS for “NHLBI TOPMed: Whole-Genome Sequencing and Related Phenotypes in the Framingham Heart Study” (phs000974.v1.p1) was performed at the Broad Institute of MIT and Harvard (HHSN268201500014C). WGS for “NHLBI TOPMed: The Jackson Heart Study” (phs000964.v1.p1) was performed at the University of Washington Northwest Genomics Center (HHSN268201100037C). WGS for “NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (phs001416.v1.p1) was performed at the Broad Institute of MIT and Harvard (HHSN268201500014C). WGS for “NHLBI TOPMed: Women’s Health Initiative (phs001237.v1.p1) was performed at the Broad Institute of MIT and Harvard (HHSN268201500014C). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sample-identity QC, and general study coordination were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.

*Framingham Heart Study (phs000974)*

WGS for “NHLBI TOPMed: Whole-Genome Sequencing and Related Phenotypes in the Framingham Heart Study” (phs000974.v1.p1) was performed at the Broad Institute of MIT and Harvard (3R01HL092577-06S1, 3U54HG003067-12S2). We also acknowledge the dedication of the FHS study participants without whom this research would not be possible.

*Jackson Heart Study (phs000964)*

The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I), and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I, and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staff and participants of the JHS.

*Multi-Ethnic Study of Atherosclerosis (phs001416)*

MESA and the MESA SHARE projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420. Also supported by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. MESA Family is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, and by the National Center for Research Resources, Grant UL1RR033176.

*Women’s Health Initiative (phs001237)*

The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.

We thank Tiffany Eulalio for her assistance in creating the graphical abstract. The graphical abstract contains images from BioRender.com.

D.N. is supported by 1T32AG047126-01. S.J. is supported by the Burroughs Wellcome Foundation Career Award for Medical Scientists, Foundation Leducq, Ludwig Center for Cancer Stem Cell Research, the American Society of Hematology Scholar Award, and the NIH Director’s New Innovator Award (DP2-HL157540). A.G.B. is supported by a Burroughs Wellcome Foundation Career Award for Medical Scientists and the NIH Director’s Early Independence Award (DP5-OD029586). We would like to thank Erik Bao for sharing his



LD reference panel and Riccardo Marioni for his assistance in obtaining GWAS summary statistics for epigenetic age acceleration.

The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

A link to the full TOPMed Banner Authorship list can be found here: (<https://www.nhlbiwgs.org/topmed-banner-authorship>).

## CONFLICT OF INTEREST

S. Jaiswal is a scientific advisor to Novartis, Roche Genentech, and Foresite Labs. UC Regents (the employer of S. Horvath and A. T. Lu) has filed patents surrounding several epigenetic biomarkers of aging (including GrimAge) which list S. Horvath and A. T. Lu as inventors. P. Natarajan reports grants support from Amgen, Apple, and Boston Scientific, and is a scientific advisor to Apple. S. Kathiresan is an employee of Verve Therapeutics and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape. G. Abecasis is an employee of Regeneron Pharmaceuticals and owns stock and stock options for Regeneron Pharmaceuticals. S. Jaiswal and S. Kathiresan have jointly filed patents relating to clonal hematopoiesis and atherosclerotic cardiovascular disease.

## AUTHOR CONTRIBUTIONS

DN and SJ performed all statistical analyses and writing of the manuscript and DN created all figures and tables. DN, SJ, AL, AB, JW, CK, TA, AP, JGW, and SH contributed to the study design and interpretation of results. AL, AB, JEM, PD, CK, AR, JGW, and SH provided feedback on the writing of the manuscript. AL, AB, PN, JW, MS, SK, GA, KT, XG, RT, PD, YL, CJ, SR, DVDB, CL, TB, GP, AC, LR, AJ, JM, JEM, PD, CK, TA, DL, JR, AR, EW, JGW, and SH contributed to data acquisition and processing.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from Trans-Omics for Precision Medicine (TOPMed) consortium. Restrictions apply to the availability of these data, which were used under license for this study. Data are available at <https://www.nhlbiwgs.org/topmed-data-access-scientific-community> with the permission of TOPMed Data Coordinating Center. All data used in the study are available at the follow DbGaP accessions: Framingham Heart Study (pfs000974.v1.p1), Jackson Heart Study (pfs000964.v4.p1), Women's Health Initiative (pfs001237.v2.p1), Multi-ethnic Study of Atherosclerosis (pfs000209.v13.p3).

## ORCID

Daniel Nachun <https://orcid.org/0000-0002-0271-1135>

Andrew D. Johnson <https://orcid.org/0000-0001-6369-5178>

Steve Horvath <https://orcid.org/0000-0002-4110-3589>

## REFERENCES

- Bick, A. G., Pirruccello, J. P., Griffin, G. K., Gupta, N., Gabriel, S., Saleheen, D., Libby, P., Kathiresan, S., & Natarajan, P. (2020). Genetic Interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. *Circulation*, *141*, 124–131.
- Bick, A. G., Weinstock, J. S., Nandakumar, S. K., Fulco, C. P., Bao, E. L., Zekavat, S. M., Szeto, M. D., Liao, X., Leventhal, M. J., Nasser, J., Chang, K., Laurie, C., Burugula, B. B., Gibson, C. J., Niroula, A., Lin, A. E., Taub, M. A., Aguet, F., Ardlie, K., ... Natarajan, P. (2020). Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature*, *586*, 763–768.
- Bild, D. E. (2002). Multi-ethnic study of atherosclerosis: Objectives and design. *American Journal of Epidemiology*, *156*, 871–881.
- Blokzijl, F., de Ligt, J., Jager, M., Sasselli, V., Roerink, S., Sasaki, N., Huch, M., Boymans, S., Kuijk, E., Prins, P., Nijman, I. J., Martincorena, I., Mokry, M., Wiegerinck, C. L., Middendorp, S., Sato, T., Schwank, G., Nieuwenhuis, E. E. S., Verstegen, M. M. A., ... van Boxtel, R. (2016). Tissue-specific mutation accumulation in human adult stem cells during life. *Nature*, *538*, 260–264.
- Bolton, K. L., Ptashkin, R. N., Gao, T., Braunstein, L., Devlin, S. M., Kelly, D., Patel, M., Berthon, A., Syed, A., Yabe, M., Coombs, C. C., Caltabellotta, N. M., Walsh, M., Offit, K., Stadler, Z., Mandelker, D., Schulman, J., Patel, A., Philip, J., ... Papaemmanuil, E. (2020). Cancer therapy shapes the fitness landscape of clonal hematopoiesis. *Nature Genetics*, *52*, 1219–1226.
- Carroll, J. E., Irwin, M. R., Levine, M., Seeman, T. E., Absher, D., Assimes, T., & Horvath, S. (2017). Epigenetic aging and immune senescence in women with insomnia symptoms: Findings from the women's health initiative study. *Biological Psychiatry*, *81*, 136–144.
- Chen, B. H., Marioni, R. E., Colicino, E., Peters, M. J., Ward-Caviness, C. K., Tsai, P.-C., Roetker, N. S., Just, A. C., Demerath, E. W., Guan, W., Bressler, J., Fornage, M., Studenski, S., Vandiver, A. R., Moore, A. Z., Tanaka, T., Kiel, D. P., Liang, L., Vokonas, P., ... Horvath, S. (2016). DNA methylation-based measures of biological age: Meta-analysis predicting time to death. *Aging*, *8*, 1844–1865.
- Christiansen, L., Lenart, A., Tan, Q., Vaupel, J. W., Aviv, A., McGue, M., & Christensen, K. (2016). DNA methylation age is associated with mortality in a longitudinal Danish twin study. *Aging Cell*, *15*, 149–154.
- Feinleib, M., Kannel, W. B., Garrison, R. J., McNamara, P. M., & Castelli, W. P. (1975). The Framingham offspring study. Design and preliminary data. *Preventive Medicine*, *4*, 518–525.
- Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., Vuong, J., Jacob, S., Muralidhar, V., Robertson, A. A. B., Cooper, M. A., Andrés, V., Hirschi, K. K., Martin, K. A., & Walsh, K. (2017). Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science*, *355*, 842–847.
- Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M. M., Slovak, M. L., ... Haase, D. (2012). Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*, *120*, 2454–2465.
- Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sada, S., Klotzle, B., Bibikova, M., Fan, J.-B., Gao, Y., Deconde, R., Chen, M., Rajapakse, I., Friend, S., Ideker, T., & Zhang, K. (2013). Genome-wide methylation profiles reveal quantitative views of human aging rates. *Molecular Cell*, *49*, 359–367.
- Hoang, M. L., Kinde, I., Tomasetti, C., McMahon, K. W., Rosenquist, T. A., Grollman, A. P., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2016). Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, *113*, 9846–9851.





- Horvath, S. (2011). *Weighted network analysis*. Springer, New York. <http://link.springer.com/10.1007/978-1-4419-8819-5>
- Horvath, S. (2013). DNA methylation age of human tissues and cell types. *Genome Biology*, 14, R115.
- Horvath, S., Gurven, M., Levine, M. E., Trumble, B. C., Kaplan, H., Allayee, H., Ritz, B. R., Chen, B., Lu, A. T., Rickabaugh, T. M., Jamieson, B. D., Sun, D., Li, S., Chen, W., Quintana-Murci, L., Fagny, M., Kober, M. S., Tsao, P. S., Reiner, A. P., ... Assimes, T. L. (2016). An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. *Genome Biology*, 17, 171.
- Horvath, S., Oshima, J., Martin, G. M., Lu, A. T., Quach, A., Cohen, H., Felton, S., Matsuyama, M., Lowe, D., Kabacik, S., Wilson, J. G., Reiner, A. P., Maierhofer, A., Flunkert, J., Aviv, A., Hou, L., Baccarelli, A. A., Li, Y., Stewart, J. D., ... Raj, K. (2018). Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and *ex vivo* studies. *Aging*, 10, 1758–1775.
- Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nature Reviews Genetics*, 19, 371–384.
- Houseman, E. A., Accomando, W. P., Koestler, D. C., Christensen, B. C., Marsit, C. J., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2012). DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics*, 13, 86.
- Jaiswal, S., & Ebert, B. L. (2019). Clonal hematopoiesis in human aging and disease. *Science*, 366, eaan4673.
- Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., ... Ebert, B. L. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. *New England Journal of Medicine*, 371, 2488–2498.
- Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberger, D., ... Ebert, B. L. (2017). Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *New England Journal of Medicine*, 377, 111–121.
- Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Hou, L., Baccarelli, A. A., Stewart, J. D., Li, Y., Whitsel, E. A., Wilson, J. G., Reiner, A. P., Aviv, A., Lohman, K., Liu, Y., Ferrucci, L., & Horvath, S. (2018). An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*, 10, 573–591.
- Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., Hou, L., Baccarelli, A. A., Li, Y., Stewart, J. D., Whitsel, E. A., Assimes, T. L., Ferrucci, L., & Horvath, S. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging*, 11, 303–327.
- Lu, A. T., Seebach, A., Tsai, P.-C., Sun, D., Quach, A., Reiner, A. P., Kooperberg, C., Ferrucci, L., Hou, L., Baccarelli, A. A., Li, Y., Harris, S. E., Corley, J., Taylor, A., Deary, I. J., Stewart, J. D., Whitsel, E. A., Assimes, T. L., Chen, W., ... Horvath, S. (2019). DNA methylation-based estimator of telomere length. *Aging*, 11(16), 5895–5923. <https://doi.org/10.18632/aging.102173>
- Lu, A. T., Xue, L., Salfati, E. L., Chen, B. H., Ferrucci, L., Levy, D., Joehanes, R., Murabito, J. M., Kiel, D. P., Tsai, P.-C., Yet, I., Bell, J. T., Mangino, M., Tanaka, T., McRae, A. F., Marioni, R. E., Visscher, P. M., Wray, N. R., Deary, I. J., ... Horvath, S. (2018). GWAS of epigenetic aging rates in blood reveals a critical role for TERT. *Nature Communications*, 9, 387.
- Marioni, R. E., Shah, S., McRae, A. F., Chen, B. H., Colicino, E., Harris, S. E., Gibson, J., Henders, A. K., Redmond, P., Cox, S. R., Pattie, A., Corley, J., Murphy, L., Martin, N. G., Montgomery, G. W., Feinberg, A. P., Fallin, M. D., Multhaup, M. L., Jaffe, A. E., ... Deary, I. J. (2015). DNA methylation age of blood predicts all-cause mortality in later life. *Genome Biology*, 16, 25.
- Martincorena, I., & Campbell, P. J. (2015). Somatic mutation in cancer and normal cells. *Science*, 349, 1483–1489.
- Perna, L., Zhang, Y., Mons, U., Holleczeck, B., Saum, K.-U., & Brenner, H. (2016). Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort. *Clin Epigenetics*, 8, 64.
- Quach, A., Levine, M. E., Tanaka, T., Lu, A. T., Chen, B. H., Ferrucci, L., Ritz, B., Bandinelli, S., Neuhauser, M. L., Beasley, J. M., Snetselaar, L., Wallace, R. B., Tsao, P. S., Absher, D., Assimes, T. L., Stewart, J. D., Li, Y., Hou, L., Baccarelli, A. A., ... Horvath, S. (2017). Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. *Aging*, 9, 419–446.
- Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., ... Glynn, R. J. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. *New England Journal of Medicine*, 377, 1119–1131.
- Risques, R. A., & Kennedy, S. R. (2018). Aging and the rise of somatic cancer-associated mutations in normal tissues. *PLOS Genetics*, 14(1), e1007108. <https://doi.org/10.1371/journal.pgen.1007108>
- Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, 43, e47.
- Robertson, N. A., Hillary, R. F., McCartney, D. L., Terradas-Terradas, M., Higham, J., Sproul, D., Deary, I. J., Kirschner, K., Marioni, R. E., & Chandra, T. (2019). Age-related clonal haemopoiesis is associated with increased epigenetic age. *Current Biology*, 29, R786–R787.
- Sempos, C. T., Bild, D. E., & Manolio, T. A. (1999). Overview of the Jackson Heart Study: A study of cardiovascular diseases in African American Men and Women. *The American Journal of the Medical Sciences*, 317, 142–146.
- Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., Kandoth, C., Fulton, R. S., McLellan, M. D., Dooling, D. J., Wallis, J. W., Chen, K., Harris, C. C., Schmidt, H. K., Kalicki-veizer, J. M., ... Wilson, R. K. (2012). The origin and evolution of mutations in acute myeloid leukemia. *Cell*, 150, 264–278.
- Wolf, E. J., Maniates, H., Nugent, N., Maihofer, A. X., Armstrong, D., Ratanatharathorn, A., Ashley-Koch, A. E., Garrett, M., Kimbrel, N. A., Lori, A., Mid-Atlantic, V. A., Workgroup, M. I. R. E. C. C., Aiello, A. E., Baker, D. G., Beckham, J. C., Boks, M. P., Galea, S., Geuze, E., Hauser, M. A., ... Logue, M. W. (2018). Traumatic stress and accelerated DNA methylation age: A meta-analysis. *Psychoneuroendocrinology*, 92, 123–134.
- Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgerisson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., Jonasson, J. G., Tryggvadottir, L., Jonsson, T., Helgason, A., Gylfason, A., Sulem, P., Rafnar, T., Thorsteinsdottir, U., Gudbjartsson, D. F., ... Stefansson, K. (2017). Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. *Blood*, 130, 742–752.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Nachun D, Lu AT, Bick AG, et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. *Aging Cell*. 2021;20:e13366. <https://doi.org/10.1111/accel.13366>